Bio-Techne Corporation shows a stable presence in the biotechnology sector with a core focus on life sciences reagents and diagnostic solutions. The company's diversified offerings in protein sciences and genomics present a balanced opportunity for growth. However, its fundamental scores reflect moderate performance, indicating room for improvement.
Bio-Techne Corporation's fundamental scores reveal a mixed performance across different metrics, with opportunities for improvement in certain areas.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow (DCF) | 3 | |
| Return on Equity (ROE) | 2 | |
| Return on Assets (ROA) | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
The historical data provides insight into the changes in Bio-Techne Corporation's scores over a short period.
| Date | Overall | DCF | ROE | ROA | Debt/Eq | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-10-23 | 2 | 3 | 2 | 4 | 1 | 1 | 2 |
| - | 0 | 3 | 2 | 4 | 1 | 1 | 2 |
Analyst estimates suggest a consistent price target for Bio-Techne Corporation, reflecting market expectations based on its current performance and future outlook.
| High | Low | Median | Consensus |
|---|---|---|---|
| 73 | 73 | 73 | 73 |
Analyst sentiment toward Bio-Techne Corporation remains positive, with a significant number of buy recommendations indicating confidence in the company's future performance.
| Recommendation | Count | Percentage |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 18 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 0 |
Bio-Techne Corporation offers a solid foundation in biotechnology with potential growth in diagnostics and genomic solutions. Despite its strengths, fundamental scores indicate some areas for improvement, particularly in financial metrics like debt to equity and price to earnings ratios. The positive analyst sentiment and stable price targets reflect market confidence, suggesting a favorable outlook if operational performance can be enhanced.